Last updated: February 22, 2026
What is NDC 60429-0969?
NDC 60429-0969 corresponds to a specific formulation of a pharmaceutical product licensed by the FDA. Based on available data, this NDC identifies Rituximab-Ravel (brand: Riabni), a biosimilar antibody used primarily for treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, or rheumatoid arthritis. It received FDA approval in 2020.
Market Overview
Product Status and Indications
- Type: Biosimilar monoclonal antibody
- Approved indications: Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis
- Regulatory status: Approved but competing with original biologics (e.g., Rituxan/MabThera) and other biosimilars
Market Size and Trends
- Global monoclonal antibody market (2022): Estimated at $154 billion (Grand View Research [1])
- Biosimilars share: Approximates 20% of the monoclonal antibody market, projected to reach 35% by 2027 (EvaluatePharma [2])
- Rituximab biosimilars: Estimated to account for 25-30% of the Rituximab market in 2023 (IQVIA [3])
Competitive Landscape
- Leading Original Product: Rituxan (Roche)
- Key Biosimilar Competitors: Truxima (Novartis), Ruxience (Pfizer), Blitzima (Celltrion), Riabni (Rani Therapeutics)
- Pricing dynamics: Biosimilars priced 15-30% below the originator; increases pressure on market share and margins (Pharma Intelligence [4])
Adoption Factors
- Physician Experience and Confidence: Slower adoption initially due to prescriber familiarity with original biologic
- Reimbursement landscape: Favorable in many regions, often with substitution policies
- Patient access: Improved due to lower prices and insurance coverage
Price Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per vial |
Notes |
| 2020 |
$2,500 |
Initial launch price for Riabni |
| 2021 |
$2,300 |
Slight decrease amid multiple biosimilar launches |
| 2022 |
$2,100 |
Continued price competition; volume growth |
Current Pricing (2023)
- Average price per 100 mg vial: $2,100–$2,300 [5]
- Market average discount from originator: 15-25%
Projected Pricing Trends (2024–2026)
- 2024: Price stabilized around $2,000–$2,200 per vial due to increased biosimilar adoption
- 2025: Potential decline to $1,850–$2,050 per vial, driven by further biosimilar entry
- 2026: Price may decrease further to $1,700–$1,900, as biosimilar competition intensifies
Revenue Projections
Assuming annual utilization of 2 million vials, based on current market share:
| Year |
Projected Volume (vials) |
Average Price per vial |
Revenue (USD) |
| 2023 |
2,000,000 |
$2,200 |
$4.4 billion |
| 2024 |
2,200,000 |
$2,100 |
$4.62 billion |
| 2025 |
2,400,000 |
$1,900 |
$4.56 billion |
| 2026 |
2,500,000 |
$1,800 |
$4.5 billion |
Revenue is projected to plateau slightly or decline due to pricing erosion, despite volume increases.
Key Market Drivers and Risks
- Competitive Entry: Increasing biosimilar launches intensify price pressure.
- Regulatory Pathways: Variability in approval pathways (e.g., interchangeability) may influence market penetration.
- Reimbursement Policies: Supportive policies can facilitate biosimilar uptake; restrictive formulary decisions can suppress growth.
- Physician Acceptance: More familiarity with biosimilars reduces resistance, accelerating market share gains.
Regulatory Outlook
- Biosimilar approval policies in the U.S. favor rapid entry, with FDA’s approval process being streamlined relative to originators.
- Interchangeability designation, which facilitates automatic substitution at pharmacy level, remains crucial. Riabni has not yet received this designation.
Summary
| Aspect |
Details |
| Market Size (2022) |
$154 billion (monoclonal antibodies) |
| Biosimilar Penetration |
20% of the monoclonal antibody market in 2022 |
| NDC 60429-0969 (Riabni) |
Entered market in 2020, pricing ~$2,200 per vial |
| Price Trend (2024–2026) |
Declines to ~$1,700–$1,900 per vial |
| Revenue Outlook |
~$4.5 billion annually with volume growth |
Key Takeaways
- Biosimilar market share will increase through 2026, exerting downward pressure on prices.
- Current pricing reductions are driven by competitive launches and payer policies.
- Volume growth is positive but may not offset price erosion, leading to plateauing revenue.
- Regulatory developments, especially interchangeability status, could accelerate adoption.
- Market remains competitive with original biologics retaining significant market share despite biosimilar options.
FAQs
1. How does biosimilar pricing compare to the original biologic?
Biosimilars typically cost 15-30% less than the originator, with prices stabilizing or declining as more biosimilars enter the market.
2. What factors influence biosimilar adoption?
Physician familiarity, reimbursement policies, interchangeability designation, and price discounts drive adoption rates.
3. Are there regional price differences?
Yes. The U.S. market generally exhibits higher prices than Europe, where pricing is more strictly regulated.
4. How might regulatory changes impact prices?
Interchangeability approvals could foster automatic substitution, increasing biosimilar uptake and further reducing prices.
5. What is the forecasted market share for Riabni?
By 2026, biosimilars including Riabni could hold close to 30-35% of the Rituximab market segment.
References
[1] Grand View Research. (2022). Monoclonal Antibodies Market Size, Share & Trends.
[2] EvaluatePharma. (2022). Biosimilars Market Report.
[3] IQVIA. (2023). Market Insights on Biosimilar Adoption Trends.
[4] Pharma Intelligence. (2022). Biosimilars Pricing and Market Penetration.
[5] Industry Sources. (2023). Current Biosimilar Pricing Data.
